Search Results
Your search for ,dUe matches 5584 pages
Showing 1801 - 1850Subgroup Analysis of Japanese Patients With Ovarian Cancer Treated With Maintenance Olaparib/Bevacizumab
Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented by Fujiwara et al at the ESMO Asia Virtual Congress 2020 showed that the addition of olaparib to bevacizumab maintenance following standard platinum-based therapy plus bevacizumab provided a progression-free...
Social Needs May Be Linked to Low Health-Related Quality of Life Among Black Cancer Survivors
Social needs—such as food and economic insecurity, poor housing and neighborhood conditions, and lack of access to transportation—were common in a group of Black cancer survivors in Detroit. These factors were associated with lower health-related quality of life, according to findings published by...
Preoperative Radiotherapy Dose Reduction in Patients With Myxoid Liposarcoma
In the phase II DOREMY trial reported in JAMA Oncology, Lansu et al found that a reduction in preoperative radiotherapy dose was effective and associated with reduced morbidity in patients with myxoid liposarcoma. A stated by the investigators, “Currently, preoperative radiotherapy for all...
ELNEC Project Reaches Historic Milestone in End-of-Life Care
The End-of-Life Nursing Education Consortium (ELNEC) project is ending 2020 by surpassing a goal established 20 years ago, reporting more than 1 million nurses and other professionals trained using the ELNEC curriculum. Administered through a partnership between the American Association of Colleges ...
Mohs Surgery vs Wide Local Excision for Trunk and Extremity Melanomas: Comparable Overall Survival Rates
A cohort study of 188,862 cases of all-stage melanomas of the trunk and extremities found no differences in overall survival between patients treated with Mohs micrographic surgery or with wide local excision.1 “These findings add to the existing body of evidence demonstrating that wide local...
Penn Medicine Researchers Receive $5.4 Million Grant to Find Genetic Drivers of Testicular Cancer
The international hunt to find more genetic risk markers for testicular cancer is expanding. A team of researchers led by Katherine L. Nathanson, MD, Deputy Director of the Abramson Cancer Center and the Pearl Basser Professor for BRCA-Related Research in the Perelman School of Medicine at the...
No Benefit of Adjuvant Sorafenib in Intermediate- or High-Risk Renal Cell Carcinoma
In a phase III trial (SORCE) reported in the Journal of Clinical Oncology, Tim Eisen, FMedSci, FRCP, PhD, of Cambridge University Hospitals NHS Foundation Trust, and colleagues found no disease-free survival benefit with 3 years of sorafenib vs placebo as adjuvant therapy in patients with renal...
A Daughter of Immigrants Chooses a Challenging but Rewarding Career in Surgical Oncology
Nationally recognized oncologic surgeon Sandra L. Wong, MD, MS, FASCO, FACS, was born and raised in Stockton, California, a city on the San Joaquin River, in California’s Central Valley. “My parents were both immigrants, but unlike the stereotypical picture of hard-driving immigrant parents who...
Study Shows Equivalence of Sentinel Node Biopsy vs Neck Node Dissection in Operable Oral or Oropharyngeal Cancer
In the French phase III Senti-MERORL trial reported in the Journal of Clinical Oncology, Renaud Garrel, MD, PhD, of the University Hospital Center of Montpellier, France, and colleagues, found that sentinel node biopsy was equivalent to neck lymph node dissection in 2-year neck node...
Darolutamide Improves Overall Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: ARAMIS Trial
As reported in The New England Journal of Medicine by Karim Fizazi, MD, of the Institut Gustave Roussy, University of Paris-Saclay, Villejuif, and colleagues, the phase III ARAMIS trial has shown significantly prolonged overall survival with darolutamide vs placebo in men with nonmetastatic...
Ixazomib Maintenance in Patients With Newly Diagnosed Multiple Myeloma Who Did Not Receive ASCT
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, Greece, and colleagues, the phase III TOURMALINE-MM4 trial has shown that postinduction maintenance with ixazomib prolonged progression-free survival vs placebo in...
Final Efficacy Results From ExteNET Trial of Neratinib in Subgroup of Patients With HR-Positive, HER2-Positive Early Breast Cancer
In an analysis from the phase III ExteNET trial reported in Clinical Breast Cancer, Arlene Chan, MD, of the Breast Cancer Research Centre of Western Australia and Curtin University, Perth, and colleagues, found significant improvements in efficacy outcomes with administration of neratinib vs...
Understanding the Uniqueness of Cancer and Survival in Adolescents and Young Adults
Numerous studies over the past 4 decades have chronicled the lack of progress in improved outcomes for adolescents and young adults (AYAs)—defined by the National Cancer Institute as those ranging in age from 15 to 39—diagnosed with cancer compared with children and older adults diagnosed with the...
Venetoclax in Combination Therapy for Untreated Acute Myeloid Leukemia
On October 16, 2020, venetoclax was granted regular approval for use in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or those with comorbidities precluding intensive induction...
A Urologic Surgeon Assesses the Current State of Prostate Cancer
Despite decades of research, multinational clinical trials, regular guideline updates by the U.S. Preventive Services Task Force, and coordinated efforts by ASCO and other major oncology organizations, the management strategy for prostate cancer remains controversial. To keep the oncology community ...
Support Builds for Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Based on early results in clinical trials, interest in the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma has been high, especially for products targeting B-cell maturation antigen (BCMA). During the ASCO20 Virtual Scientific Program, further support for CAR T-cell...
Pembrolizumab in Adult and Pediatric Classical Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 14, 2020, the approval of pembrolizumab was...
Mode of Detection of High-Risk Breast Cancer Linked to Prognosis
Breast cancers detected between mammographic screenings carry a worse prognosis than those detected at the time of screening, even when tumor biology is similar, according to research presented at the 12th European Breast Cancer Conference (EBCC 12), which was held virtually this year.1 The 8-year...
Hairy Cell Leukemia Foundation and Leukemia & Lymphoma Society Join Forces
The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) recently announced they are teaming up to support a research grants program of up to $10 million over 5 years. Their goal is to build a more comprehensive understanding of hairy cell leukemia, develop better...
Can Antihypertensives Improve Outcomes With Immunotherapy?
Angiotensin receptor blockers, commonly used to treat hypertension, may improve outcomes in patients treated with anti–PD-1/L1 agents, according to an observational study of almost 600 patients reported at the virtual 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.1 The...
Expert Point of View: Melina E. Marmarelis, MD, MSCE
Invited study discussant, Melina E. Marmarelis, MD, MSCE, of Abramson Cancer Center at the University of Pennsylvania, Philadelphia, noted that pembrolizumab has been evaluated in advanced mesothelioma in several clinical trials, with varying results. According to Dr. Marmarelis, this high...
Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158
The largest single-arm trial evaluating pembrolizumab in relapsed malignant pleural mesothelioma has demonstrated an “impressive” duration of response, according to a presentation during the virtual edition of the International Association for the Study of Lung Cancer (IASLC) 2020 North America...
Nagi S. El Saghir, MD, FACP, FASCO, Receives Lebanon’s National Cedar Medal Award
One of Lebanon’s highest national awards, the National Cedar Medal (Commander Rank), was recently bestowed upon Nagi S. El Saghir, MD, FACP, FASCO, in recognition of his extensive contributions to the fields of medicine, education, and science—and most particularly, for his efforts in the fight...
Management of Painful Spinal Metastases: SBRT vs Conventional Radiotherapy
Stereotactic body radiation therapy (SBRT) was superior to conventional radiation therapy in reducing pain from spinal metastases in a phase II/III study reported at the virtual edition of the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 More than twice as many patients...
Impact of COVID-19 on Cancer Care in India
With the announcement of a complete nationwide lockdown on March 25, 2020, to prevent the spread of COVID-19, a lot of unprecedented events came into being in India. The National Health Mission reported a 69% reduction in measles, mumps, and rubella vaccination in children; a 21% reduction in...
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in The Lancet by Grosicki et al, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly bortezomib/dexamethasone in previously treated patients with multiple myeloma. Study Details...
ESMO Asia 2020: Futibatinib for Patients With Refractory Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements
Clinical benefit was provided by the FGFR1–4 inhibitor futibatinib in patients with refractory intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements, including those enrolled in Asian countries. These findings were presented by Furuse et al at the ESMO Asia Virtual...
Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer
In a single-institution phase II trial reported in JAMA Oncology, Zsiros et al found that the combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide produced objective response in approximately half of women with recurrent ovarian cancer taking part in the study....
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the treatment of patients with chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on...
Carfilzomib vs Bortezomib, Each Combined With Lenalidomide/Dexamethasone, in Newly Diagnosed Patients With Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, of the Division of Hematology, Mayo Clinic, Rochester, and colleagues,1 the phase III ENDURANCE trial has shown no improvement in progression-free survival with carfilzomib plus lenalidomide/dexamethasone (KRd) vs bortezomib plus...
Support Builds for Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Based on early results in clinical trials, interest in the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma has been high, especially for products targeting B-cell maturation antigen (BCMA). During the ASCO20 Virtual Scientific Program, further support for CAR T-cell...
Does Supplementation With Vitamin D Reduce the Risk of Developing Advanced Cancer?
The Vitamin D and Omega-3 Trial (VITAL), which was completed in 2018, found that vitamin D did not reduce overall incidence of cancer, but it hinted at a decreased risk of cancer deaths. Now, in a secondary analysis of VITAL, a research team focused on the connection between taking vitamin D...
Study Results With PET-Directed Therapy for Limited-Stage DLBCL
As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, of the University of Arizona Cancer Center, Tucson, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Role of Rituximab in Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
The European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) recently reported a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma (B-NHL) following the...
Addition of Rituximab to Standard Chemotherapy Improves Event-Free and Overall Survival in Children With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial, reported in TheNew England Journal of Medicine, -Véronique Minard-Colin, MD, PhD, of Gustave Roussy, Université Paris-Saclay, Villejuif, France, and colleagues found that the addition of rituximab ...
State of Lung Cancer Report Finds People of Color Face Greater Burden, Worse Lung Cancer Outcomes in the United States
People of color diagnosed with lung cancer face worse outcomes compared to White Americans, according to the American Lung Association’s third annual State of Lung Cancer report. The 2020 State of Lung Cancer report tracks the toll of lung cancer by state, and for the first time, this year’s report ...
Paclitaxel Plus Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer: Long-Term Follow-up and Genomic Analysis
In a 7-year follow-up of the phase III CALGB 40601/Alliance neoadjuvant trial reported in the Journal of Clinical Oncology, Fernandez-Martinez et al found that paclitaxel combined with trastuzumab/lapatinib was associated with improved survival outcomes vs paclitaxel/trastuzumab in women with...
Cancer Deaths Linked to 4 Million Potential Years of Life Lost in 2017
Deaths from cancer accounted for more than 4 million potential years of life lost in 2017, according to a study published by Minkyo Song, MD, PhD, and colleagues in Cancer Epidemiology, Biomarkers & Prevention. While the cancer types with the highest death rates per capita accounted for the...
Virtual Mind-Body Services for Patients With Cancer During the COVID-19 Pandemic
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, focus on the role of virtual...
Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic
A portion of patients with cancer may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic. According to a report published as a research letter by Mark E. Fleury, PhD, and colleagues in JAMA Oncology, nearly one in five patients with cancer surveyed said the...
Meta-analysis of Outcomes With Gamma Knife Radiosurgery for Uveal Melanoma or Ocular Metastases
In a systematic review and meta-analysis reported in The Lancet Oncology, Parker et al found that Gamma Knife radiosurgery was associated with high local control and tumor regression rates in patients with uveal melanoma or intraocular metastases. As stated by the investigators, “Gamma [K]nife...
Adjuvant Irinotecan/Cisplatin vs Etoposide/Cisplatin for Resected High-Grade Neuroendocrine Carcinoma of the Lung
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant irinotecan/cisplatin did not improve relapse-free survival vs etoposide/cisplatin in patients with completely resected, pathologic stage I–IIIA, high-grade neuroendocrine carcinoma of the...
Expert Point of View: Therese Marie Mulvey, MD, FASCO
Therese Marie Mulvey, MD, FASCO, Director of Quality Safety and Value at the Massachusetts General Hospital North Shore Cancer Center, Boston, told The ASCO Post that this “provocative and elegant” study underscores the importance of listening to patients. “Baseline patient-reported symptoms are...
Addition of Indoximod to Taxane Chemotherapy in First-Line Treatment of HER2-Negative Metastatic Breast Cancer
In a phase II trial reported in JAMA Oncology, Mariotti et al found that the addition of the indoleamine 2,3-dioxygenase 1 (IDO1) pathway inhibitor indoximod to a taxane did not improve progression-free survival in first-line treatment of patients with metastatic HER2-negative breast cancer. As...
Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer
In a United Arab Emirates single-institution study reported as a research letter in JAMA Oncology, Al-Shamsi et al found a high rate of COVID-19 infection among asymptomatic patients with solid tumors undergoing cancer treatment. Study Details The study included 109 patients receiving treatment for ...
Closing the Gap in Integrative Oncology Education
Launched in 2018 at the University of Michigan Medical School in Ann Arbor, the Integrative Oncology Scholars Program has trained 50 oncology professionals in evidence-based complementary therapies in the treatment of patients with cancer. Another 50 trainees are expected to complete the program by ...
Reduced Breast Cancer Mortality and Risk of Recurrence With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer
As reported in The Lancet Oncology by Philip M. Poortmans, PhD, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reductions in both breast cancer mortality and recurrence with postsurgery internal mammary and medial supraclavicular (IM-MS) lymph node chain...
An Emergency Room Physician Explores Her Own Healing Through a Life of Medical Service
Medical memoir dramas, especially those centered in the emergency room (ER), are often met with the anticipation of top-rated medical shows portrayed on TV, in which there is nonstop blood-and-guts action and sizzling tensions between shouting doctors and nurses. In her recently published memoir,...
ASTRO Honors 2020 Gold Medalists
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2020 Gold Medal awards and other honors at the 62nd ASTRO Annual Meeting, which was held online due to the COVID-19 pandemic. ASTRO Gold Medal Bruce Haffty, MD, FASTRO, and Brian O’Sullivan, MD, FASTRO, were each...
